{"id":16877,"date":"2024-09-29T09:46:59","date_gmt":"2024-09-29T07:46:59","guid":{"rendered":"https:\/\/inmuno.es\/?page_id=16877"},"modified":"2024-09-29T09:48:41","modified_gmt":"2024-09-29T07:48:41","slug":"journal-of-leukocyte-biology","status":"publish","type":"page","link":"https:\/\/inmuno.es\/index.php\/journal-of-leukocyte-biology\/","title":{"rendered":"Journal of Leukocyte Biology"},"content":{"rendered":"<ul class=\"wp-block-latest-posts__list is-grid columns-3 has-dates has-author wp-block-latest-posts\"><li><a class=\"wp-block-latest-posts__post-title\" href=\"http:\/\/jitc.bmj.com\/cgi\/content\/short\/14\/6\/e015176?rss=1\">Immune checkpoint inhibitor neurotoxicity: long-term outcomes with focus on 1-year neurological sequelae<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-24T16:41:25+02:00\" class=\"wp-block-latest-posts__post-date\">24 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">\nBackground\nData on the long-term course of neurological immune-related adverse events (n-irAEs) are limited by the size of studies as well as short and heterogeneous follow-up durations. Herein, we assessed the risk and predictors of 1-year neurologic&#8230;<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"http:\/\/jitc.bmj.com\/cgi\/content\/short\/14\/6\/e014768?rss=1\">Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-24T16:41:25+02:00\" class=\"wp-block-latest-posts__post-date\">24 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">\nBackground\nPathologic tumor response and changes in the tumor microenvironment (TME) predict outcomes to immune checkpoint inhibitors, but are understudied in rare tumors. We investigated whether artificial intelligence (AI)-powered analyses of pretre&#8230;<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"http:\/\/jitc.bmj.com\/cgi\/content\/short\/14\/6\/e013748?rss=1\">Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-24T16:41:25+02:00\" class=\"wp-block-latest-posts__post-date\">24 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">\nBackground\nThe programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) is used as a biomarker to predict benefit from immune checkpoint blockade (ICB) in patients with non-small cell lung cancer (NSCLC). However, additional biomarkers are neede&#8230;<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"http:\/\/jitc.bmj.com\/cgi\/content\/short\/14\/6\/e015100?rss=1\">Targeting non-canonical antigens unlocks functional T-cell responses in renal cell carcinoma<\/a><div class=\"wp-block-latest-posts__post-author\">by Wang, J., Zhu, Y., He, X., Yin, S., He, Y., Yao, P., Li, J., Li, X., Shi, P., Qian, R., Xiao, Z., Ye, X., Xi, J. J., Ye, B.<\/div><time datetime=\"2026-06-24T16:41:25+02:00\" class=\"wp-block-latest-posts__post-date\">24 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">\nBackground\nRenal cell carcinoma (RCC) frequently exhibits favorable responses to immunotherapy, despite a low tumor mutational burden, suggesting a critical role for non-mutational antigens presented by human leukocyte antigen class I in activating CD&#8230;<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"http:\/\/jitc.bmj.com\/cgi\/content\/short\/14\/6\/e014421?rss=1\">Spatial immune atlas of breast cancer brain metastasis reveals CD163+ macrophage reprogramming associated with immune escape<\/a><div class=\"wp-block-latest-posts__post-author\">by Zhu, J., Ye, J., Ma, Y., Lin, Z., Wen, Y., Sheng, J., Yang, M.<\/div><time datetime=\"2026-06-24T16:41:25+02:00\" class=\"wp-block-latest-posts__post-date\">24 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">\nBackground\nBrain metastases (BrM) remain a major cause of mortality in breast cancer (BC), yet the spatial organization and molecular circuitry of the metastatic immune microenvironment are poorly defined.\n\nMethods\nTo address this gap, we integrated h&#8230;<\/div><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":16879,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-16877","page","type-page","status-publish","has-post-thumbnail"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/16877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=16877"}],"version-history":[{"count":1,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/16877\/revisions"}],"predecessor-version":[{"id":16878,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/16877\/revisions\/16878"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media\/16879"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=16877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}